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Purpose: There is no clinically useful therapy for the suppression of vein bypass graft intimal 
hyperplasia (IH). Photodynamic therapy (PDT), a technique that uses light to activate 
otherwise biologically inert photosensitizers to produce cytotoxic effects, has been 
demonstrated to successfidly inhibit experimental IH  in balloon-injured arteries. The 
purpose of this study was to investigate he efficacy of PDT as a method to reduce vein graft 
IH. 
Methods: Reversed external jugular vein bypass grafts of the common carotid artery were 
performed in 28 male Sprague-Dawley rats. The animals received either chloroaluminum 
sulfonated phthalocyanine (2.5 mg/kg intravenously) 24 hours before the ex vivo 
irradiation of the vein grafts (VG) with 100 jouie/cm 2 at 675 nm (PDT VG) or saline 
solution as control (CON VG). Preharvest bromodeoxyuridine was administered to label 
proliferating cells. All vein grafts were perfusion fixed within 96 hours for a pilot study 
or at 2 and 4 weeks for the main study. Histology, immunohistochemistry, and 
morphometric analysis were performed. 
Results: There was no acute thrombus formation in the hypocelluiar PDT VG with 
occasional platelets but no leukocytes adherent to the luminal surface. Intimal areas of the 
PDT VG were 18% at 2 weeks and 53% at 4 weeks of the CON VGs (2 < 0.05). Medial 
areas and percent of stenoses were also significantly less in PDT than in CON VG. 
However, intimal hyperplasia noted in the longitudinal sections within 2 mm of the 
anastomoses did not demonstrate a difference between PDT and CON VG. Intimal 
hyperplasia of both PDT and CON VG consisted of smooth muscle cells, verified by 
immunohistochemistry. Bromodeoxyuridine-labeled ceilswere more abundant in 2-week 
than in 4-week specimens, were found most frequently in the intimal areas of the CON 
VG body, and were equivalent in the anastomoses of PDT VG and CON VG. 
Conclusions: These data suggest that PDT of vein grafts suppresses the development o f lH  
in the body of the vein graft but does not affect IH  adjacent to the anastomoses. The artery 
may be the source of proliferating smooth muscle ceils that contribute to the anastomotic 
vein graft IH. (J VASC SURG 1995;21:882-90.) 
The saphenous vein is accepted as the best conduit 
for small- and medium-sized arterial reconstruction. 
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Nevertheless, even this conduit is not ideal. In fact, 
vein grafts used for femoropopliteal reconstruction 
have been reported to develop an occlusion rate of  
30% to 35% during the first 2 to 3 years after implan- 
tation. 2 Studies of aortocoronary vein grafts found 
occlusion rates of 4% to 12% at 2 weeks and at 2 
months, with a yearly attrition rate of 2% to 5%. 3,4 
The main causes of the vein graft failure were stenotic 
lesions in the body of the graft and at the anasto- 
moses. There was no reported correlation of vein 
graft failure to valve sites, tributaries, clamp sites, or 
residual valve cusps, s Stenotic lesions resulted most 
frequently from intimal hyperplasia (IH) and were 
responsible for 65% to 75% of all vein graft failures 
that occurred within the first postoperative y ar. 6 
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Table I. Morphometric analysis of VG 
2 weeks* 
CON VG (n = 4) PDT VG (n = 5) 
4 weeks* 
CON VG (n = s) PDT VG (n = 4) 
Intimal area (mm 2) 0.148 + 0.109 0.029 + 0.011t 0.124 -+ 0.038 0.066 + 0.027?$ 
Medial area (ram 2) 0.174 -+ 0.037 0.114 - 0.034? 0.145 + 0.024 0.085 -+ 0.020t 
Luminal stenosis (%) 6.8 -+ 3.4 1.6 + 0.7? 12.4 -+- 3.4~ 5.3 + 2.2t$ 
Diameter (ram) 1.69 + 0.16 1.55 -+ 0.14 1.13 -+ 0.075 1.32 +- 0.26 
BrdU anastomosis§ 9.33 -- 2.05 16.5 + 3.41 7.67 + 1.85 4.67 -+ 1.72 
BrdU vein graft body§ 7.17 -- 2.04 1.33 - 0.54 4.00 + 0.47 1.17 -+ 0.4 
BrdU, Bromodeoxyruidine. 
*Mean _+ SEM. 
tp < 0.05 CON VG versus PDT VG. 
Sp < 0.05 2 weeks versus 4 weeks. 
§Cells per 400 x field. 
IH, a response to various types of vascular wall 
injuries, is the narrowing of the vascular lumen 
resulting from smooth muscle cell (SMC) migration 
to the subendothelial space and proliferation. This 
multifactorial process is triggered and regulated by 
numerous growth factors and cytoldnes.7 Subsequent 
production of matrix contributes tothe development 
of a luminal stenosis. 
In vein grafts, two types of lH are described. The 
first is IH due to migration and proliferation of the 
vein's own medial SMC in the body of the graft, and 
this entity is represented astruncal IH. The second 
entity is anastomotic IH caused by SMC at and across 
the anastomoses, which may be derived, in part, from 
the artery and the vein graft. 81° Causes of nonacute 
vein graft stenoses were found to be from anasto- 
motic IH (62%), atherosclerotic changes (20%), and 
external compression of the graft (10%). n 
Although the mechanisms of lH are yet to be fully 
understood, a number of drugs have been tested for 
the prevention of vein graft IH. Some of these drugs 
such as heparin 121s have demonstrated inconclusive 
results, whereas others such as angiotensin- 
converting enzyme inhibitors, fish oil, and angiopep- 
tin have no proven clinical efficacy. 16q8 
Photodynamic therapy (PDT), another ap- 
proach being investigated for the inhibition of 
experimental IH, is a biologic application of 
photochemistry) 9-23 Light energy is delivered to 
tissue where it activates previously administered, 
otherwise inert, photosensitive drugs. Once light 
activates the photosensitizer, f ee radical moieties 
are produced, either by the photosensitizer itself or 
by energy transfer to ambient 0 2 . These free radicals 
result in cytotoxic effects. 
Many photosensitizer drugs are available for PDT 
photochemistry. Chloroaluminum sulfonated phtha- 
locyanine (CASPc) is a powerful second generation 
photosensitizer that, at therapeutic systemic doses, 
has no skin photosensitivity, a problem noted with 
many porphyrin photosensitizers) 9 
PDT has been demonstrated to decrease cell 
proliferation i several diseases, including experimen- 
tal and human cancer. 2426 For the inhibition of 
experimental IH, PDT depletes SMC without appar- 
ent compromise to the arterial wall. Despite the 
elimination of SMC in the artery wall, there is no 
visible cellular inflammatory esponse and no arterial 
wall degeneration but cellular repopulation of the 
arterial scaffold over time. 23,27 
Strong evidence suggests that PDT can inhibit 
experimental IH in the different models of balloon- 
injured arteries. This study was designed to deter- 
mine whether PDT might also have a role in the 
treatment of vein graft IH. 
METHODS 
Surgery. Twenty-eight male Sprague-Dawley 
rats weighing 350 to 400 gm (Charles River Labo- 
ratories, Wilmington, Mass.) were anaesthetized 
with intramuscular ketamine (75 mg/kg) and xyla- 
zine (5 mg/kg). With an operating microscope 
(Codman & Shurtlett, Inc., Randolph, Mass.) the 
distal segment of the left external jugular vein (Fig. i) 
was carefully harvested, gently placed on a PE-10 
tube stent, and immersed in Ringer's lactate solution 
containing heparin (10 U/ml). For PDT, the vein 
grafts of the experimental group (PDT VG) were 
irradiated, whereas the control veins (CON VG) 
remained inphosphate-buffered saline solution with- 
out irradiation for a comparable time (25 minutes). 
Subsequently, a portion of the left common carotid 
artery was resected before replacement with the 
reversed vein interposition graft. The anastomoses 
were performed with interrupted 10-0 nylon sutures 
(Ethicon, Inc., Somerville, N.J.). There was no size 
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Fig. 1. Schematic of model used. Distal external jugular vein, sit proceeds deep into neck, is 
harvested, reversed, and sutured to cervical common carotid artery s bypass graft. 
mismatch evident between the vein graft and artery 
after reconstituting blood flow. 
PDT regimen. Twenty-four hours before ca- 
rotid artery bypass surgery, animals of the PDT- 
treated group were injected intravenously with 2.5 
mg/kg CASPc (CIBA-GEIGY, Basel, Switzerland). 
At the time of bypass, the segment of harvested 
external jugular vein was gently flushed of blood, 
stented, and fixed by a bridged microclamp. This 
arrangement allowed rotating the vein graft 180 
degrees to provide a more uniform external irradia- 
tion of the tissue. Vein grafts were immersed in 
phosphate-buffered saline solution and externally 
irradiated ex vivo with the argon-pumped dye laser 
(Coherent IN-NOVA I 100 and Coherent CR599; 
Coherent, Palo Alto, Calif.) at 675 um at a uniform 
irradiance of 100 mW/cm 2 for a total delivered 
fluence of 100 joule/cm 2.19 
Harvest. A pilot study of PDT-treated vein 
grafts included six rats that were harvested at 24 to 96 
hours. For the main study nine animals (five PDT VG 
and four CON VG) were killed at 2 weeks, and nine 
animals (four PDT VG and five CON VG) were 
killed at 4 weeks after surgery. Animals received 
bromodeoxyuridine (Sigma Chemical Co., St. Louis, 
Mo.) 100 mg/kg intramuscularly, at 18 and 12 hours 
before sacrifice. After anticoagulation with 1000 U 
heparin and euthanasia, the animals were infused 
with Hanks' solution at 80 mm Hg pressure, 
exsanguinated, and perfusion fixed with 10% buff- 
ered formalin. Specimens included vein grafts with 
adjacent artery and segments of small bowel and  
contralateral carotid artery, which served as immu- 
nohistochemistry controls. 
The animal procedures were approved by the 
Institutional Animal Care Committee and complied 
with the "Principles of Laboratory Animal Care" and 
the Guide for the Care and Use of Laboratory Animals 
(NIH Publication No. 80-23, revised 1985). 
Histology. The harvested vein graft specimens 
were processed into three segments: proximal anas- 
tomosis, vein graft body, and distal anastomosis. 
Cross-sections were prepared from the vein graft 
body, whereas longitudinal sections were obtained 
from the anastomoses. Specimens were stained with 
hematoxylin and eosin, with Masson's trichrome for 
collagen, and Verhoef?s elastin stains. Intimal and 
medial areas were measured bymorphometric anal- 
ysis with a camera lucida digitizing measurement 
system (Sigma Scan; Jandel Scientific, Sausalito, 
Calif.). 2a The luminal stenosis was calculated as a 
percent of the intimal area over the total rea within 
the internal elastic lamina area. The vein graft 
diameter was calculated from the circumference 
measured as the length of the internal elastic lamina. 
On longitudinal sections, IH was measured across 
JOURNAL OF VASCULAR SURGERY 
Volume 21, Number 6 LaMuraglia et al. 885 
! i ¸¸  ili ili 
Fig. 2. Light micrograph of representative s ction from 4-week control vein graft. Note thin 
media and IH with multiple layers of smooth muscle cells.Arr0w denotes internal elastic lamina. 
Hematoxylin and eosin stain. Bar equals 25 p.m. 
the anastomoses a thickness from the internal elastic 
lamina. 
Immtmohistochemistry. Four-micrometer- 
thick sections were deparaffinized through xylenes 
and rehydrated with graded alcohol. Specimens were 
prepared as previously described with the primary 
antibody HHF-35 (Biogenics, San Ramon, Calif.) 
for smooth muscle specific actin or bromodeoxyuri- 
dine (Cell Proliferation Kit; Amersham, Arlington 
Heights, Ill.) for detection of S-phase in mitosis 
to assess cell proliferation. 23 Bromodeoxyuridine- 
labeled nuclei were then counted in three random 
400 X fields per specimen to assess the number of 
positive cells and compared with HHF-35-stained 
slides to identify proliferating SMC. 
Statistical Analysis. All data within experimen- 
tal groups were expressed as mean -+ SEM. Differ- 
ences between groups were evaluated where appro- 
priate with either one-way analysis of variance or a 
Student test. Ap  value less than 0.05 was regarded 
as significant. 
RESULTS 
All vein grafts were patent at harvest. Four 
animals, two PDT VG and two CON VG, died in the 
early phase of this study and were excluded from the 
analysis. No animals appeared to develop skin 
photosensitivity. Histologic study of the PDT VG in 
the pilot study demonstrated no acute thrombus 
formation. Microscopically, platelets but not poly- 
morphonuclear leukocytes were seen on the intimal 
surface. Rare nuclei were seen in the vein graft media. 
Eighteen rats were used for the main, long-term 
study. There was no evidence of graft dilation or 
aneurysm present in any vein grafts. At harvest here 
was less inflammation around the PDT VG, which 
were easier to dissect han CON VG. 
Microscopically at 2 weeks after surgery, CON 
VG developed typical IH  consisting of 8 to 10 layers 
of SMC with collagen and some elastin matrix (Fig. 
2). Occasional polymorphonuclear cells could be seen 
in the CON VG adventitia. In the PDT VG (Fig. 3), 
IH  was identified on an occasional specimen, but it 
consisted of only two to three layers of SMC. In 
contrast o CON VG, PDT VG had a significantly 
reduced adventitial inflammatory infiltrate. No sub- 
stantial difference in structure between 2- and 4-week 
vein grafts was found within each group. Endothelial 
cells were noted in both CON VG and PDT VG 
sections. Anastomotic hyperplasia ppeared equiva- 
lent in CON VG and PDT VG with SMC present 
primarily in the vein graft portion of the anastomoses 
(Fig. 4). 
The results of morphometric analyses are shown 
in Table I. In PDT VG, there was a fivefold decrease 
of intimal area at 2 weeks and almost a twofold 
decrease at 4 weeks compared with corresponding 
CON VG (p < 0.05). The percent luminal stenosis 
reflected the findings of the intimal area (Table I). 
The medial area o fPDT VG was also consistently ess 
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Fig. 3. Light micrograph of representative section fr m 4-week PDT vein graft. No IH is 
present. Note collapsed media and compact adventitia. Arrow denotes internal elastic lamina. 
Hematoxylin and eosin stain. Bar equals 25 ~m. 
Fig. 4. Light micrograph of 4-week anastomotic hyperplasia of PDT vein graft. Smooth 
muscle cells appear to be emanating (arrow) from artery wall edge with black elastic laminae into
IH. Verhoeff's elastin stain. Bar equals 50 ~m. 
at 2 and 4 weeks compared with CON VG 
(p < 0.05). There was a significant decrease in CON 
VG diameter noted between week 2 and week 4 
(p < 0.05). Although this trend existed in PDT VG, 
it was not statistically significant. 
Anastomotic longitudinal morphometric analyses 
are shown in Figs. 5 and 6. IH was not characteristic 
for the arterial portion of the anastomoses xcept at 
the distal anastomoses of the 4-week PDT VG. There 
was no statistically significant difference between 
PDT VG and CON VG IH across the anastomoses 
at 2 and 4 weeks. 
Immunohistochemistry with HHF-35 for SMC- 
specific actin verified that the IH present at the 
anastomosis and body of vein grafts consisted of 
SMC. CON VG had positive staining results in the 
media, whereas PDT VG had no cells in the media. 
Results of immunohistochemistry to delineate cell 
proliferation by bromodeoxyuridine-positive nuclei 
are listed in Table I. In all groups there was more 
evidence of cellular proliferation at 2 versus 4 weeks. 
There were no noted differences between CON VG 
and PDT VG bromodeoxyuridine labeling at the 
anastomoses; however, in the PDT VG body there 
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Fig. 6. Distribution f intimal hyperplasia at distal anas-
tomoses. IH is measured at 2 weeks (A) and 4 weeks (B) 
between PDT (closed circles) and control (open squares) vein 
grafts at distances in ram. 
was rare labeling and only in the adventitia. The 
immunohistochemistry verified that most of the 
proliferating cells in CON VG media and intima 
stained positive for SMC-specific actin. 
DISCUSSION 
The pathogenesis of vein graft IH, a significant 
problem in vascular surgery, is not fully un@rstood. 
Vein graft IH may be a purely adaptive response to 
arterialization with limited cellular proliferation and 
matrix deposition. However, as an exaggerated 
response to injury, IH may play a pivotal role in the 
development of stenoses and clinical vein graft 
failures. In this study, we demonstrated that, when 
experimental vein grafts are subjected to PDT before 
implantation, the development of IH in the body of 
the graft is diminished, resulting in less luminal 
stenosis. However, anastomotic IH is not affected by 
this treatment. Therefore these data suggest that the 
origin of the SMC causing vein graft body and 
anastomotic IH may be different. 
Previous results from this laboratory indicated 
that PDT can effectively prevent the development of
IH in the balloon-injured rat carotid artery. 19,z3 
Initially acellular without evidence of an inflamma- 
tory reaction to the cytotoxic effects of PDT, the 
intima of PDT-treated arteries eventually develops 
endothelial cell covering as suggested by scanning 
electron microscopy? 3 Long-term studies demon- 
strated rare SMC repopulation of the media, and only 
the occasional PDT-treated artery developed IH by 
16 weeks. Despite these findings there was neither 
artery dilation nor an increased compliance sugges- 
tive of weakening of the vessel wall. 23,27 These results, 
confirmed by others, 28 demonstrated favorable long- 
term healing of the artery after PDT. The data from 
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these arterial studies prompted this investigation 
with a similar PDT regimen used to determine the 
feasibility of IH inhibition in the vein graft model. A 
lower concentration of the photosensitizer CASPc 
was used because the relatively thinner venous wall 
was believed to facilitate drug diffusion and light 
penetration as compared with the artery. 
The hypothesis of this study was that PDT 
depletion of cells from the vein graft and production 
of a stable collagen scaffold would prevent vein graft 
IH or dilation. In fact, the results of this investigation 
support this hypothesis and demonstrated many 
similarities with the PDT effects on arteries. PDT 
produced a hypocellular vein graft without inflam- 
mation in the vessel wall. Loss of endothelial cells in 
the vein graft after PDT did not cause increased 
thrombogenicity. Over time cell repopulation oc- 
curred in the intima and adventitia of PDT-treated 
vein grafts. IH was substantially reduced by PDT as 
compared with CON VG in the body of the graft. 
IH in vein grafts has been reported, in part, to be 
a result of the adaptation to the tangential stress 
experienced by the vessel wall during exposure to 
arterial circulation. 29 In the cited study, which used a 
rabbit model, intimal areas and diameters continued 
to increase over the 24 weeks examined. However, 
our data reflected a stabilization of CON VG intimal 
and medial areas and a decrease of the diameters at the 
2- and 4-week time points examined. This may reflect 
the different design of this study, which provided 
similar sized animals at the time of euthanasia to 
correct for possible growth differences. The decrease 
of the CON VG diameters, which were isometric 
with the adjacent artery at the time of implantation, 
may reflect vein graft fibrosis. Vein grafts treated with 
PDT may not contain the necessary cells to produce 
the fibrosis, which resulted in the diameter reduction 
noted at 4 weeks in CON VG. 
Photodynamic therapy did not affect anastomotic 
vein graft IH in this model. Despite cell depletion in 
the PDT VG, the histologic structure, cell prolifera- 
tion, and amount of IH at the anastomoses were 
virtually the same compared with CON VG at 2 and 
4 weeks. Immunohistochemistry confirmed these 
anastomotic IH cells ofPDT VG and CON VG to be 
SMC. 
Compliance mismatch may be a contributing 
factor to the anastomotic IH noted in both PDT and 
CON VG. Reported increased compacmess of the 
collagen in the adventitia of PDT-treated arteries 
occurred over time and leads to a decrease in dynamic 
compliance of the artery wall as compared with 
non-PDT-treated arteries. 27 The degree of compli- 
ance mismatch present at the anastomosis has been 
reported to affect the amount of IH that develops 
primarily beyond the distal anastomosis. 3°,31 Al- 
though compliance of these vein grafts or anasto- 
moses were not evaluated, the inferred compliance 
differences may explain the presence of IH  found in 
the artery at the distal anastomosis n the 4-week 
PDT VG. 
Studies have established that SMC can migrate 
from the arterial wall to the vein graft to produce IH 
in response to surgical injury. 8-1° Because our results 
demonstrated the absence of cells in the PDT VG 
acutely after treatment, he presence of anastomotic 
IH would indicate that the SMC responsible for the 
changes were of arterial origin. In fact, increased 
bromodeoxyuridine labeling of nuclei, indicative of 
proliferating cells, in the arterial media adjacent to 
and at the anastomosis supports this hypothesis. 
In conclusion, PDT suppressed vein graft IH, 
which may have a role for inhibiting stenoses of the 
vein graft body. However, PDT of the vein graft 
alone could not suppress anastomotic IH. This may 
imply a different cause of the stenosis of the vein graft 
body compared with the stenosis at the anastomotic 
site. Anastomotic vein graft IH may result from 
arterial rather than venous injury or arterialization. 
Therefore further investigations need to be under- 
taken to determine whether PDT treatment directed 
to the anastomosis can inhibit IH at those sites. 
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D ISCUSSION 
Dr. Steven Ruby (Farmington, Conn.). IH and its 
direct consequences-recurrent stenosis and vein graft 
occlusion-plague sas vascular surgeons on a daily basis. 
Our colleagues from the Massachusetts General Hospital 
have presented an elegant experiment as part of their 
relentless assault on this perplexing problem. The uniform 
response of blood vessels to injury has been catalogued in
detail but is yet to be completely understood. The initiating 
events may be a combination of mechanical, biochemical, 
physiologic, and immunologic factors. As a result, experi- 
mental and clinical interventions have been diversified. The 
goal of this experiment was to assess the role of PDT in the 
pretreatment of interposition vein grafts before their 
implementation i  a rat model, and the answer to this 
question was partially es. The good news is that IH in the 
body of the graft was essentially eliminated. The bad news 
is that where it really counts clinically at the Achilles' heel 
of what we do at the distal anastomosis, this application of 
photobiology was not effective because the origin of the 
pathologic process presumably was the adjacent artery or 
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the result of an accentuated compliance mismatch. The 
results were intriguing, and they raise more questions than 
they answer. 
There was a virtual elimination of endothelial cells as a 
result of pretreatment with laser light, yet there was no 
acute thrombosis of the vein grafts. Are we to believe that 
it is no longer advantageous to preserve healthy functioning 
endothelial cells to maintain functioning vein grafts? Why 
did the exposed collagen ot result in thrombosis? 
In this work and in all prior work with this model of 
PDT, there has been a virtual elimination of all inflamma- 
tory cells in the wall of the vessel. Like anything else, too 
much inflammation is probably a detriment; however, 
what will the ukimate healing of these grafts be like in the 
absence of any inflammatory infiltrate? 
In the manuscript you briefly touch on the compliance 
change induced by the laser treatment. Will this ultimately 
be the stumbling block? You said the vein was thin and 
blue, but on the other hand you also stated that the 
compliance was decreased, so maybe you could just 
readdress that for us. 
From a technical point of view, is there a difference 
between external irradiation of the grafts as has been done 
in this experiment and the internal application of light? If 
you change the dose or the color of the light, will you 
preserve more of the endothelial cells? 
Last, what are the clinical implications? We would have 
to conclude from this study that just excising the graft 
before implantation and bringing it to the laboratory for 
irradiation will not help with the IH at the distal 
anastomosis. What then are the practical considerations, 
and how can we now aim our attack with this technology 
on the SMC of the adjacent artery? 
Dr. Glenn M. LaMuraglia. From our previous work 
in arteries, we have known that thrombosis not a problem 
if the proper dose of PDT is used. Many things happen with 
free radicals that we are not sure of. We are starting to 
investigate some of these possibilities, changes in the artery 
wall so that the surface may be less thrombogenic than it is 
in other circumstances such as mechanical injury to the 
subendothelium or the basement membrane. 
In terms of the lack of inflammation, this is the most 
important finding and why we have continued with this 
work. Without inflammation and protein turnover in the 
vicinity of white cells, there is no weakening in the wall. As 
a result it permits cellular repopulation, as previously 
described, into the adventitia to enable ascaffolding around 
the artery and to help prevent the development of 
aneurysmal degeneration. Therefore, besides the adventi- 
tial healing, although we have not presented it, we also 
expect he endothelium to repopulate the intima of the 
vessel as we have described in our arterial model. 
Your question regarding compliance is in fact correct. 
These vessels do become stiffer over time, which probably 
relates to the adventitial healing process that occurs in these 
vessels over weeks and months. It is detrimental; however, 
there are ways of grading such a phenomenon, and one of 
the possibilities i in applying the PDT to adjoining arterial 
Surfaces. 
In terms of the questions relating to the external versus 
the internal laser irradiation. The size of these vein grafts, 
approximately 1 mm in diameter, makes it essentially an 
engineering feat to try to irradiate from the inside. We have 
used 675 nm wavelength light, which is in the red part of 
the spectrum and has a very deep penetration in tissue 
approximately 1 to 2 mm. These vein grafts were irradiated 
in vitro and were moved during the irradiation time to 
provide a homogeneous irradiation. We were testing more 
the principle than a possible clinical application at this early 
phase. 
There is no wavelength of light to deplete all the SMC 
and not the endothelial cells. However, as you know, other 
options exist such as endothelial seeding of grafts if these 
are going to be prepared in a laboratory and then placed 
into patients. 
